[
  {
    "ts": null,
    "headline": "US Equity Indexes Rise This Week as AI-Trade Lifts Tech, Healthcare Gains Following Pfizer Deal",
    "summary": "US equity indexes ended higher this week as a federal government shutdown in its early days failed t",
    "url": "https://finnhub.io/api/news?id=6b62ac183b5a695c26807571dc66235f3c095bc9b6f389696fe9ff0940d3a2c8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759525126,
      "headline": "US Equity Indexes Rise This Week as AI-Trade Lifts Tech, Healthcare Gains Following Pfizer Deal",
      "id": 136980575,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "US equity indexes ended higher this week as a federal government shutdown in its early days failed t",
      "url": "https://finnhub.io/api/news?id=6b62ac183b5a695c26807571dc66235f3c095bc9b6f389696fe9ff0940d3a2c8"
    }
  },
  {
    "ts": null,
    "headline": "5 Large Cap Drug Stocks: Values or Traps?",
    "summary": "Some drug stocks are cheap but is it another fake out?",
    "url": "https://finnhub.io/api/news?id=6b37ae979ad1261a96d773275c84229ccfdaabe06d40dae948855552f983204c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759524900,
      "headline": "5 Large Cap Drug Stocks: Values or Traps?",
      "id": 136980576,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Some drug stocks are cheap but is it another fake out?",
      "url": "https://finnhub.io/api/news?id=6b37ae979ad1261a96d773275c84229ccfdaabe06d40dae948855552f983204c"
    }
  },
  {
    "ts": null,
    "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of October 5",
    "summary": "See here for weekly updates on Dividend Champions, Contenders, and Challengers. Stay informed on dividend changes, ex-dividend, and pay dates.",
    "url": "https://finnhub.io/api/news?id=068a20268c95267376b1bc2285d270c67c66fda730a9e0758fb52630b3a138b9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759514550,
      "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of October 5",
      "id": 136967742,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "See here for weekly updates on Dividend Champions, Contenders, and Challengers. Stay informed on dividend changes, ex-dividend, and pay dates.",
      "url": "https://finnhub.io/api/news?id=068a20268c95267376b1bc2285d270c67c66fda730a9e0758fb52630b3a138b9"
    }
  },
  {
    "ts": null,
    "headline": "MRK Stock Up Nearly 14% So Far This Week: What's Driving It?",
    "summary": "Merck shares climb nearly 14% as Pfizer's landmark drug pricing deal with the Trump administration sparked renewed optimism in pharma stocks.",
    "url": "https://finnhub.io/api/news?id=8e49fe92f5a0728e930c52ffc1547ef9d062a15b03767bf598e48c84d6c4fc85",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759500360,
      "headline": "MRK Stock Up Nearly 14% So Far This Week: What's Driving It?",
      "id": 136980579,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck shares climb nearly 14% as Pfizer's landmark drug pricing deal with the Trump administration sparked renewed optimism in pharma stocks.",
      "url": "https://finnhub.io/api/news?id=8e49fe92f5a0728e930c52ffc1547ef9d062a15b03767bf598e48c84d6c4fc85"
    }
  },
  {
    "ts": null,
    "headline": "Pharma Stocks Eye Best Week in 16 Years as Trump Overhang Eases",
    "summary": "The group’s advance was spurred by Pfizer Inc. on Tuesday when it agreed to slash some of its drug prices for Americans enrolled in the Medicaid insurance program in exchange for a three-year reprieve on import tariffs.  The New York-based company also agreed to invest $70 billion in the US as part of an agreement with President Donald Trump.  The deal was seen as another sign of easing pressures on the pharmaceutical industry since the president announced possible future tariffs on drug imports in April as well as drug-pricing reforms in May. It followed Trump’s move last week to exempt companies with US manufacturing from pharmaceutical levies in the first signal of relief for the sector.",
    "url": "https://finnhub.io/api/news?id=4ed048c0b8b53dcf134371fcbdd5cfdf7bfe39a5a8cc056485e84b9d971547e8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759498087,
      "headline": "Pharma Stocks Eye Best Week in 16 Years as Trump Overhang Eases",
      "id": 136965073,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The group’s advance was spurred by Pfizer Inc. on Tuesday when it agreed to slash some of its drug prices for Americans enrolled in the Medicaid insurance program in exchange for a three-year reprieve on import tariffs.  The New York-based company also agreed to invest $70 billion in the US as part of an agreement with President Donald Trump.  The deal was seen as another sign of easing pressures on the pharmaceutical industry since the president announced possible future tariffs on drug imports in April as well as drug-pricing reforms in May. It followed Trump’s move last week to exempt companies with US manufacturing from pharmaceutical levies in the first signal of relief for the sector.",
      "url": "https://finnhub.io/api/news?id=4ed048c0b8b53dcf134371fcbdd5cfdf7bfe39a5a8cc056485e84b9d971547e8"
    }
  },
  {
    "ts": null,
    "headline": "Merck: A Race Against The Keytruda Clock",
    "summary": "Merck (MRK) is attractively valued, boasting strong free cash flow, robust margins, and a leading position in oncology with Keytruda.",
    "url": "https://finnhub.io/api/news?id=12bcf3c84901b3f96fbdb9cf54e52a7005ba213b2e56c48b6c7544974c30e09c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759497691,
      "headline": "Merck: A Race Against The Keytruda Clock",
      "id": 136966014,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1210931291/image_1210931291.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Merck (MRK) is attractively valued, boasting strong free cash flow, robust margins, and a leading position in oncology with Keytruda.",
      "url": "https://finnhub.io/api/news?id=12bcf3c84901b3f96fbdb9cf54e52a7005ba213b2e56c48b6c7544974c30e09c"
    }
  },
  {
    "ts": null,
    "headline": "What Does Wall Street Think About Merck & Co. (MRK)?",
    "summary": "Merck & Co., Inc. (NYSE:MRK) is one of the best medical stocks to buy now. On September 26, Bernstein analyst Courtney Breen maintained a Hold rating on Merck & Co., Inc. (NYSE:MRK). Similarly, Roth MKM also assigned a Hold rating to the stock on September 17 with a $90 price target. In another report released […]",
    "url": "https://finnhub.io/api/news?id=5f2b59ba7671d034f01a59e0926f6e60ac6b39891c7fdc9e357fdee98ddbab1e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759487282,
      "headline": "What Does Wall Street Think About Merck & Co. (MRK)?",
      "id": 136963209,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck & Co., Inc. (NYSE:MRK) is one of the best medical stocks to buy now. On September 26, Bernstein analyst Courtney Breen maintained a Hold rating on Merck & Co., Inc. (NYSE:MRK). Similarly, Roth MKM also assigned a Hold rating to the stock on September 17 with a $90 price target. In another report released […]",
      "url": "https://finnhub.io/api/news?id=5f2b59ba7671d034f01a59e0926f6e60ac6b39891c7fdc9e357fdee98ddbab1e"
    }
  }
]